Galapagos (NASDAQ:GLPG) Downgraded to “Reduce” Rating by Kepler Capital Markets

Galapagos (NASDAQ:GLPG) was downgraded by stock analysts at Kepler Capital Markets from a “hold” rating to a “reduce” rating in a research report issued to clients and investors on Wednesday,Briefing.com Automated Import reports.

Several other research analysts have also issued reports on the stock. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a report on Monday, September 9th. Leerink Partners began coverage on Galapagos in a report on Monday, September 9th. They issued a “market perform” rating and a $24.00 target price on the stock. Royal Bank of Canada dropped their target price on Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. Finally, Raymond James downgraded Galapagos from an “outperform” rating to a “market perform” rating in a research note on Friday, August 2nd. Two research analysts have rated the stock with a sell rating and six have given a hold rating to the stock. According to MarketBeat.com, Galapagos presently has a consensus rating of “Hold” and an average target price of $30.75.

Galapagos Price Performance

Galapagos stock opened at $26.69 on Wednesday. The stock has a fifty day moving average of $28.83 and a 200-day moving average of $27.56. Galapagos has a 52 week low of $24.16 and a 52 week high of $42.46.

Institutional Investors Weigh In On Galapagos

Institutional investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC lifted its position in shares of Galapagos by 56.7% during the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 446 shares in the last quarter. GAMMA Investing LLC increased its holdings in Galapagos by 140.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 736 shares during the period. Signaturefd LLC boosted its holdings in Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,258 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,510 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 814 shares during the period. 32.46% of the stock is owned by hedge funds and other institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.